Biomarker tests detect early Alzheimer’s pathology.

The Grace Lamsam Pharmacy Program has teamed up to serve vulnerable populations for 30 years.

Pitt research suggests that the choice of tau tracers used for brain imaging in Alzheimer’s diagnostics can change who tests positive, influencing disease detection and treatment eligibility.